# Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

> **NCT02252406** · PHASE4 · COMPLETED · sponsor: **University of Florida** · enrollment: 33 (actual)

## Conditions studied

- Stable Angina
- Metabolic Syndrome

## Interventions

- **DRUG:** Ranolazine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02252406
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-12-17
- **Final completion:** 2019-05-17
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02252406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02252406, "Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02252406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*